Focus: Blue Earth Diagnostics is a UK-based molecular imaging company specializing in positron emission tomography (PET) diagnostics across oncology, neurology, and cardiovascular disease. Founded in 2014, the company has established market presence with two FDA-approved products and an active pipeline spanning multiple therapeutic areas.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Hot — 531 jobs added in 30d
Net +497 (531 new, 34 removed). Aggressive expansion phase.
Best suited for commercial, operations, and engineering professionals seeking stability in a focused imaging diagnostics company; riskier for R&D-track scientists given pipeline opacity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA-approved molecular imaging agent with 18-year patent runway; anchors oncology diagnostic franchise.
Help build intelligence for Blue Earth Diagnostics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Blue Earth Diagnostics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second peak commercial product; extends PSMA imaging portfolio with complementary mechanism and long LOE protection.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo